J. Racha

Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes.

S. Berthel, Y. Qian, D. Choi, 2013, ACS medicinal chemistry letters.

Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.

J. Grippo, F. Matschinsky, P. Mahaney, 2012, Journal of medicinal chemistry.

Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate.

A. Rettie, K. Kunze, J. Racha, 1998, Biochemistry.

2,3-Disubstituted acrylamides as potent glucokinase activators.

J. Grippo, A. Sidduri, J. Lou, 2010, Bioorganic & medicinal chemistry letters.

Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation

N. Olejnik, D. Moore, H. Satoh, 2000, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetic Interactions with Felbamate

P. Glue, C. Banfield, R. Levy, 1997, Clinical pharmacokinetics.

A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

R. Dummer, A. Joe, J. Grippo, 2015, Pharmacology research & perspectives.

Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine.

H. Satoh, N. Olejnik, D. Moore, 2003, Drug metabolism and pharmacokinetics.

Binding of the Aflatoxin-Glutathione Conjugate to Mouse Glutathione S-Transferase A3-3 Is Saturated at Only One Ligand per Dimer*

D. Eaton, W. Atkins, K. Kunze, 1996, The Journal of Biological Chemistry.